Format

Send to

Choose Destination
Alzheimers Dement. 2017 Feb;13(2):186-195. doi: 10.1016/j.jalz.2016.07.154. Epub 2016 Oct 1.

Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project.

Author information

1
Institut National de la Sante et de la Recherche Medicale, U1061 Neuropsychiatrie, Montpellier, France; University of Montpellier, Montpellier, France; Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK. Electronic address: karen.ritchie@inserm.fr.
2
Clinical Research, Neurosciences, Janssen, South San Francisco, CA, USA.
3
Clinical Research, Neuroscience and General Medicine, Eisai Inc, Woodcliff Lake, NJ, USA.
4
Metis Cognition Ltd, Kilmington Common, UK; Alzheimer Center VUmc, Amsterdam, Holland.
5
Neurology and Biomedical Engineering, Oregon Health and Science University, Portand, OR, USA.
6
Department of Neurology Memory and Ageing Centre, University of California at San Francisco, San Francisco, CA, USA.
7
Department of Neurology, Loyola University Medical Center, Maywood, IL, USA.
8
Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK.

Abstract

The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.

KEYWORDS:

Alzheimer's disease; Cognition; Neuropsychology; Preclinical

PMID:
27702619
DOI:
10.1016/j.jalz.2016.07.154
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center